Aurinia Pharmaceuticals Stock Price

-0.76 (-4.67%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 8,221,750
Bid Price 15.25
Ask Price 15.76
News -
Day High 15.76


52 Week Range


Day Low 13.615
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aurinia Pharmaceuticals Inc AUPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.76 -4.67% 15.50 19:56:08
Open Price Low Price High Price Close Price Prev Close
15.65 13.615 15.76 15.74 16.26
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
55,021 8,221,750 $ 14.60 $ 120,004,227 - 9.72 - 33.9715
Last Trade Time Type Quantity Stock Price Currency
19:56:08 90 $ 15.50 USD


Draw Mode:

Aurinia Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.01B 129.67M 129.14M $ 46.53M $ - - -15.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -618.40k 0.30%

more financials information »

Aurinia Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AUPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week18.888519.9313.61517.483,276,168-3.39-17.94%
1 Month23.0024.4513.61519.812,786,306-7.50-32.61%
3 Months32.0033.971513.61522.464,099,142-16.50-51.56%
6 Months11.1733.971510.8520.934,403,4984.3338.76%
1 Year20.5033.97159.7217.564,155,134-5.00-24.39%
3 Years6.8533.97153.5215.832,356,3328.65126.28%
5 Years2.6533.97152.6412.542,206,55712.85484.91%

Aurinia Pharmaceuticals Description

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

Your Recent History
Aurinia Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.